<p><h1>Dengue Vaccines Market Analysis Examines its Scope on Growth Opportunities, and Forecasted Trends Spanning from 2024 to 2031.</h1></p><p><strong>Dengue Vaccines Market Analysis and Latest Trends</strong></p>
<p><p>Dengue vaccines are vaccines that provide immunity against the dengue virus, which is transmitted to humans through the bite of infected Aedes mosquitoes. The vaccines work by stimulating the immune system to produce antibodies that protect against infection.</p><p>The Dengue Vaccines Market is expected to grow at a CAGR of 13.5% during the forecast period. The market growth is driven by factors such as the increasing prevalence of dengue fever worldwide, rising awareness about the importance of vaccination, and government initiatives to control the spread of the disease.</p><p>Recent trends in the Dengue Vaccines Market include the development of new vaccines with improved efficacy and safety profiles, increasing investment in research and development activities, and collaborations between pharmaceutical companies and government organizations to accelerate vaccine development and distribution.</p><p>Overall, the Dengue Vaccines Market is witnessing significant growth and is expected to continue to expand in the coming years as efforts to combat the dengue virus intensify and demand for preventive measures increases.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliablebusinessinsights.com/enquiry/request-sample/1240236">https://www.reliablebusinessinsights.com/enquiry/request-sample/1240236</a></p>
<p>&nbsp;</p>
<p><strong>Dengue Vaccines Major Market Players</strong></p>
<p><p>Sanofi and Takeda are two key players in the Dengue Vaccines market. Sanofi, a French multinational pharmaceutical company, developed the first Dengue vaccine, Dengvaxia. However, due to safety concerns, its use has been restricted in some countries. Takeda, a Japanese pharmaceutical company, has been working on developing a novel Dengue vaccine candidate, TAK-003, which has shown promising results in clinical trials.</p><p>Sanofi has a well-established presence in the global pharmaceutical market and has been a leader in vaccine development. The company's Dengue vaccine, Dengvaxia, has been approved in several countries and has been used in numerous vaccination programs. Sanofi continues to invest in research and development to improve the safety and efficacy of Dengvaxia.</p><p>Takeda has been making significant strides in the Dengue vaccine market with its candidate, TAK-003. In clinical trials, TAK-003 has demonstrated strong immune response and protection against Dengue fever. Takeda is committed to bringing this vaccine to market and addressing the unmet need for Dengue prevention.</p><p>The Dengue vaccine market is expected to grow significantly in the coming years due to the increasing incidence of Dengue fever worldwide. Both Sanofi and Takeda are well-positioned to tap into this growth opportunities with their respective Dengue vaccine candidates.</p><p>In terms of sales revenue, Sanofi reported total sales of â‚¬36.5 billion in 2020, with a significant portion coming from its vaccine division. Takeda, on the other hand, reported total revenue of $30.9 billion in the same year, with a focus on expanding its vaccine portfolio.</p><p>Overall, both Sanofi and Takeda are key players in the Dengue vaccines market with strong capabilities in research and development. As the market continues to grow, these companies are expected to play a significant role in meeting the demand for effective Dengue vaccines.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Dengue Vaccines Manufacturers?</strong></p>
<p><p>The global Dengue Vaccines market is experiencing significant growth with increasing awareness about dengue prevention and government initiatives to control the spread of the disease. The market is expected to witness a CAGR of around 17% during the forecast period 2021-2026. Factors such as rising incidences of dengue fever, growing investments in research and development activities, and technological advancements in vaccine production are driving the market growth. Developing regions such as Asia-Pacific are expected to offer lucrative opportunities for market players. The future outlook for the Dengue Vaccines market looks promising with continued advancements in vaccine development.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliablebusinessinsights.com/enquiry/pre-order-enquiry/1240236">https://www.reliablebusinessinsights.com/enquiry/pre-order-enquiry/1240236</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Dengue Vaccines Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Dengvaxia</li><li>TAK-003</li><li>Others</li></ul></p>
<p><p>Dengue vaccines market is segmented into three main types: Dengvaxia, TAK-003, and others. Dengvaxia is the first approved vaccine for Dengue fever, developed by Sanofi Pasteur. TAK-003 is another promising vaccine candidate currently in clinical trials, showing potential for preventing all four Dengue virus serotypes. Other vaccines in the market include those developed by various pharmaceutical companies, each offering unique approaches to combating Dengue fever. The diversity in vaccine types reflects the ongoing efforts to address the global burden of Dengue disease.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliablebusinessinsights.com/purchase/1240236">https://www.reliablebusinessinsights.com/purchase/1240236</a></p>
<p>&nbsp;</p>
<p><strong>The Dengue Vaccines Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Public Sector</li><li>Private Sector</li></ul></p>
<p><p>Dengue vaccines have applications in both the public and private sectors. In the public sector, governments and non-profit organizations administer vaccines to large populations to prevent outbreaks and reduce the burden on healthcare systems. In the private sector, pharmaceutical companies develop and distribute vaccines to individuals for profit. Both sectors play a crucial role in controlling the spread of dengue virus and safeguarding public health.</p></p>
<p><a href="https://www.reliablebusinessinsights.com/dengue-vaccines-r1240236">&nbsp;https://www.reliablebusinessinsights.com/dengue-vaccines-r1240236</a></p>
<p><strong>In terms of Region, the Dengue Vaccines Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The growth of dengue vaccines market is expected to be most pronounced in the Asia-Pacific region, particularly China, due to high incidence rates of dengue fever. North America, Europe, and the USA are also expected to contribute significantly to market expansion. By 2025, APAC is projected to dominate the global dengue vaccines market with a market share of 40%, followed by North America at 30%, Europe at 20%, USA at 5%, and China at 5%.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliablebusinessinsights.com/purchase/1240236">https://www.reliablebusinessinsights.com/purchase/1240236</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliablebusinessinsights.com/enquiry/request-sample/1240236">https://www.reliablebusinessinsights.com/enquiry/request-sample/1240236</a></p>
<p><strong></strong></p>
<p><p><a href="https://github.com/gcimaudf65/Market-Research-Report-List-1/blob/main/affordable-luxury-fashion-market.md">Affordable Luxury Fashion Market</a></p><p><a href="https://github.com/pennyaldbrittonh658/Market-Research-Report-List-1/blob/main/adult-animation-market.md">Adult Animation Market</a></p><p><a href="https://github.com/dmmanir420/Market-Research-Report-List-1/blob/main/due-diligence-investigation-market.md">Due Diligence Investigation Market</a></p></p>